Tirzepatide

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It has been described as the first compound characterized in the class of dual incretin receptor agonists.

Dual Receptor Targeting

This synthetic 39-amino-acid peptide engages both GIP and GLP-1 receptors. Research has focused on whether combined activation of these two incretin pathways produces effects that differ from single-receptor activation.

Molecular Design

The peptide structure is modified with a C20 fatty diacid moiety that promotes reversible albumin binding, which extends its circulating half-life in laboratory models.

Tirzepatide functions as an agonist at both GIP and GLP-1 receptors. Research investigates the effects of this dual activation on pathways related to glucose metabolism and energy balance.

Published nonclinical literature relevant to this material's molecular targets and experimental models is listed below for independent review. Findings involving other preparations or experimental systems should not be attributed to this research material.

This material is supplied solely for in vitro and other nonclinical laboratory research. It is not for human or veterinary use, consumption, administration, therapeutic use, or diagnostic use.

Laboratory Handling

Handle only in an appropriately equipped laboratory using applicable institutional procedures, personal protective equipment, and the storage conditions shown for the material. The purchaser is responsible for study design, handling controls, disposal, and regulatory compliance.

Research Limitations

Published observations involving other preparations, experimental systems, or study populations do not establish the identity, performance, or suitability of this research material for any particular experiment.